First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study

被引：6

作者：

Dieras, Veronique ^{[1
]}

Pop, Simona ^{[1
]}

Berger, Frederique ^{[2
,3
]}

Dujaric, Marie-Eglantine ^{[2
]}

Beuzeboc, Philippe ^{[1
]}

Escalup, Laurence ^{[4
]}

Bidard, Francois Clement ^{[1
,3
]}

Cottu, Paul Henri ^{[1
]}

Le Tourneau, Christophe ^{[1
]}

Piperno-Neumann, Sophie ^{[1
]}

Laurence, Valerie ^{[1
]}

Robain, Mathieu ^{[2
]}

Asselain, Bernard ^{[2
]}

Pierga, Jean-Yves ^{[1
,5
]}

机构：

[1] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France

[2] PSL Res Univ, Inst Curie, Biostat Unit, Paris, France

[3] PSL Res Univ, Inst Curie, INSERM, U900, Paris, France

[4] PSL Res Univ, Inst Curie, Pharm Dept, Paris, France

[5] Descartes Univ Paris, Paris, France

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 03期

关键词：

Bevacizumab; metastatic breast cancer; first-line; paclitaxel; HER2-negative; PHASE-III TRIAL; PLUS BEVACIZUMAB; OPEN-LABEL; THERAPY; CHEMOTHERAPY; CAPECITABINE; COMBINATION; DOCETAXEL;

D O I：

10.21873/anticanres.11462

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (mBC) at a single centre with a homogenous standard-of-care. Patients and Methods: Information on patient and disease characteristics, efficacy, and safety was extracted from computer-based records of all patients receiving first-line bevacizumabpaclitaxel at the Curie Institute, Paris, France, between 2008 and 2011. Results: Median progression-free survival in the 116 treated patients was 13.2 months; median overall survival was 38.4 months. Corresponding values were 9.0 and 18.8 months, respectively, in patients with triple-negative mBC, and 19.4 and 58.8 months, respectively, in patients receiving maintenance endocrine therapy. No new safety signals were seen. Conclusion: Outcomes in patients treated with bevacizumab-paclitaxel at our center were consistent with efficacy in prospective clinical trials, with notable activity in poor-prognosis disease. Maintenance endocrine or oral therapy with bevacizumab after paclitaxel discontinuation was associated with long-term disease control.

引用

页码：1403 / 1407

页数：5

共 13 条

[1] Bevacizumab in the first-line treatment of metastatic breast cancer [J].

Cameron, David .

EJC SUPPLEMENTS, 2008, 6 (06) :21-28

[2] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy [J].

Fabi, Alessandra ;

Russillo, Michelangelo ;

Ferretti, Gianluigi ;

Metro, Giulio ;

Nistico, Cecilia ;

Papaldo, Paola ;

De Vita, Ferdinando ;

D'Auria, Giuliana ;

Vidiri, Antonello ;

Giannarelli, Diana ;

Cognetti, Francesco .

BMC CANCER, 2012, 12

[3] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial [J].

Gligorov, Joseph ;

Doval, Dinesh ;

Bines, Jose ;

Alba, Emilio ;

Cortes, Paulo ;

Pierga, Jean-Yves ;

Gupta, Vineet ;

Costa, Romulo ;

Srock, Stefanie ;

de Ducla, Sabine ;

Freudensprung, Ulrich ;

Mustacchi, Giorgio .

LANCET ONCOLOGY, 2014, 15 (12) :1351-1360

[4] First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients [J].

Miles, D. W. ;

Dieras, V. ;

Cortes, J. ;

Duenne, A. -A. ;

Yi, J. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2013, 24 (11) :2773-2780

[5] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation [J].

Miles, David ;

Cameron, David ;

Bondarenko, Igor ;

Manzyuk, Lyudmila ;

Alcedo, Juan Carlos ;

Lopez, Roberto Ivan ;

Im, Seock-Ah ;

Canon, Jean-Luc ;

Shparyk, Yaroslav ;

Yardley, Denise A. ;

Masuda, Norikazu ;

Ro, Jungsil ;

Denduluri, Neelima ;

Hubeaux, Stanislas ;

Quah, Cheng ;

Bais, Carlos ;

O'Shaughnessy, Joyce .

EUROPEAN JOURNAL OF CANCER, 2017, 70 :146-155

[6] Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].

Miles, David W. ;

Chan, Arlene ;

Dirix, Luc Y. ;

Cortes, Javier ;

Pivot, Xavier ;

Tomczak, Piotr ;

Delozier, Thierry ;

Sohn, Joo Hyuk ;

Provencher, Louise ;

Puglisi, Fabio ;

Harbeck, Nadia ;

Steger, Guenther G. ;

Schneeweiss, Andreas ;

Wardley, Andrew M. ;

Chlistalla, Andreas ;

Romieu, Gilles .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3239-3247

[7] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].

Miller, Kathy ;

Wang, Molin ;

Gralow, Julie ;

Dickler, Maura ;

Cobleigh, Melody ;

Perez, Edith A. ;

Shenkier, Tamara ;

Cella, David ;

Davidson, Nancy E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676

[8]

Redondo Andres, 2014, Onco Targets Ther, V7, P2175, DOI 10.2147/OTT.S70654

[9] RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer [J].

Robert, Nicholas J. ;

Dieras, Veronique ;

Glaspy, John ;

Brufsky, Adam M. ;

Bondarenko, Igor ;

Lipatov, Oleg N. ;

Perez, Edith A. ;

Yardley, Denise A. ;

Chan, Stephen Y. T. ;

Zhou, Xian ;

Phan, See-Chun ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1252-1260

[10] Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) [J].

Rugo, Hope S. ;

Barry, William T. ;

Moreno-Aspitia, Alvaro ;

Lyss, Alan P. ;

Cirrincione, Constance ;

Leung, Eleanor ;

Mayer, Erica L. ;

Naughton, Michael ;

Toppmeyer, Deborah ;

Carey, Lisa A. ;

Perez, Edith A. ;

Hudis, Clifford ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (21) :2361-U57

← 1 2 →